Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis

PHASE3CompletedINTERVENTIONAL
Enrollment

239

Participants

Timeline

Start Date

May 24, 2019

Primary Completion Date

September 13, 2022

Study Completion Date

September 13, 2022

Conditions
HyperphosphatemiaEnd Stage Renal DiseaseESRD
Interventions
DRUG

Ferric citrate tablet

250mg/tablet, manufactured by Sinomune Pharmaceutical

DRUG

Sevelamer carbonate tablet

800 mg/tablet, manufactured by Genzyme Ireland Limited

Trial Locations (20)

Unknown

The first affiliated hospital of Baotou medical college, Baotou

Beijing Tongren Hospital, Beijing

Peking Union Medical College Hospital, Beijing

The Second Xiangya Hospital of Central South University, Changsha

Xiangya Hospital Central South University, Changsha

The second hospital of Dalian medical university, Dalian

The affiliated hospital of Inner Mongolia Medical University, Hohhot

The second people's hospital of Huaian, Huai'an

Jinan central hospital, Jinan

Shandong province Qianfoshan hospital, Jinan

Zhongnan Hospital Southeast University, Nanjing

The people's hospital of Guangxi Zhuang Autonomous Region, Nanning

Shenzhen people's hospital, Shenzhen

The third hospital of Hebei medical university, Shijiazhuang

General Hospital of Tianjin Medical University, Tianjin

The First Affiliated Hospital of Xinjiang Medical University, Ürümqi

First Affiliated Hospital of Zhengzhou University, Zhengzhou

Henan provincal people's hospital, Zhengzhou

Zhengzhou People's Hospital, Zhengzhou

Zhuzhou Central Hospital, Zhuzhou

All Listed Sponsors
lead

Sinomune Pharmaceutical Co., Ltd

INDUSTRY

NCT04456803 - Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis | Biotech Hunter | Biotech Hunter